STAT+: Capsida says it still doesn’t know what caused gene therapy death
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Capsida Biotherapeutics said it still has no explanation for the September death of a child in its CAP‑002 gene‑therapy trial.
- Capsida Biotherapeutics reports the hospital conducting the trial has refused to share autopsy tissue samples, blocking its scientists from pinpointing the cause.
- CAP-002 is a first‑in‑class brain‑penetrating gene therapy designed to cross the blood‑brain barrier, part of a surge in viral‑vector treatments for rare and neurodegenerative diseases.
Why it matters: Capsida Biotherapeutics loses crucial data needed to explain the fatal outcome, delaying CAP‑002’s progress and shaking investor confidence, while families and the broader gene‑therapy field suffer from reduced safety transparency.
